The clinical impact of frailty in transplant ineligible patients with multiple myeloma treated with bortezomib-based chemotherapy as front line therapy

被引：0

作者：

Lee, Ho Sup ^{[1
]}

Kim, Da Jung ^{[1
]}

Lee, Ji Hyun ^{[2
]}

Lee, Je-Jung ^{[3
]}

Jung, Sung-Hoon ^{[3
]}

Jo, Jae-Cheol ^{[4
]}

Lee, Yoo Jin ^{[4
]}

Shin, Ho-Jin ^{[5
]}

Lee, Won ^{[6
]}

机构：

[1] Kosin Univ, Coll Med, Busan, South Korea

[2] Dong A Univ, Coll Med, Busan, South Korea

[3] Chonnam Natl Univ, Hwasun Hosp, Hwasun Gun, Jeollanam Do, South Korea

[4] Ulsan Univ Hosp, Ulsan, South Korea

[5] Pusan Natl Univ Hosp, Busan, South Korea

[6] Busan Paik Hosp, Busan, South Korea

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

bortezomib; frailty; Multiple myeloma;

D O I：

10.1016/j.clml.2019.09.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-015

引用

页码：E11 / E12

页数：2

共 50 条

[1] Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial [J].

Atsushi Isoda ;

Kayoko Murayama ;

Shigeki Ito ;

Yoichi Kohara ;

Masaki Iino ;

Yuri Miyazawa ;

Morio Matsumoto ;

Hiroshi Handa ;

Yosuke Imai ;

Takuro Ishiguro ;

Wataru Izumita ;

Kiyoshi Kitano ;

Yukio Hirabayashi ;

Hideyuki Nakazawa ;

Fumihiro Ishida ;

Toru Mitsumori ;

Keita Kirito ;

Takaaki Chou ;

Hirokazu Murakami .

International Journal of Hematology, 2018, 108 :39-46

[2] Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial [J].

Isoda, Atsushi ;

Murayama, Kayoko ;

Ito, Shigeki ;

Kohara, Yoichi ;

Iino, Masaki ;

Miyazawa, Yuri ;

Matsumoto, Morio ;

Handa, Hiroshi ;

Imai, Yosuke ;

Ishiguro, Takuro ;

Izumita, Wataru ;

Kitano, Kiyoshi ;

Hirabayashi, Yukio ;

Nakazawa, Hideyuki ;

Ishida, Fumihiro ;

Mitsumori, Toru ;

Kirito, Keita ;

Chou, Takaaki ;

Murakami, Hirokazu .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 108 (01) :39-46

[3] Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma [J].

Ludwig, Heinz ;

Drach, Johannes ;

Graf, Helmut ;

Lang, Alois ;

Meran, Johannes Gobertus .

HAEMATOLOGICA, 2007, 92 (10) :1411-1414

[4] Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data [J].

Sandecka, Viera ;

Pour, Ludek ;

Spicka, Ivan ;

Minarik, Jiri ;

Radocha, Jakub ;

Jelinek, Tomas ;

Heindorfer, Adriana ;

Pavlicek, Petr ;

Sykora, Michal ;

Jungova, Alexandra ;

Kessler, Petr ;

Wrobel, Marek ;

Starostka, David ;

Ullrychova, Jana ;

Stejskal, Lukas ;

Stork, Martin ;

Straub, Jan ;

Pika, Tomas ;

Brozova, Lucie ;

Sevcikova, Sabina ;

Maisnar, Vladimir ;

Hajek, Roman .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (04) :466-474

[5] Clinical outcomes of bortezomib-based therapy in myeloma [J].

Djebbari, Faouzi ;

Srinivasan, Anandagopal ;

Valiance, Grant ;

Moore, Sally ;

Kothari, Jaime ;

Ramasamy, Karthik .

PLOS ONE, 2018, 13 (12)

[6] Bortezomib and lenalidomide as front-line therapy for multiple myeloma [J].

Zou, Yandun ;

Lin, Mingzhen ;

Sheng, Zhixin ;

Niu, Shaona .

LEUKEMIA & LYMPHOMA, 2014, 55 (09) :2024-2031

[7] Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction [J].

Mollee, Peter ;

Boyle, Stephen ;

Wellard, Cameron ;

Moore, Elizabeth ;

Blacklock, Hilary ;

Harrison, Simon J. ;

Ho, P. Joy ;

Hocking, Jay ;

McQuilten, Zoe ;

Quach, Hang ;

Spearing, Ruth ;

Wood, Erica ;

Spencer, Andrew .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) :E233-E234

[8] Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project [J].

Franchi, Matteo ;

Vener, Claudia ;

Garau, Donatella ;

Kirchmayer, Ursula ;

Di Martino, Mirko ;

Romero, Marilena ;

De Carlo, Ilenia ;

Scondotto, Salvatore ;

Stival, Chiara ;

Della Porta, Matteo Giovanni ;

Passamonti, Francesco ;

Corrao, Giovanni .

THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12

[9] Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma [J].

Bumma, Naresh ;

Dhakal, Binod ;

Fraser, Raphael ;

Estrada-Merly, Noel ;

Anderson, Kenneth ;

Freytes, Cesar O. ;

Hildebrandt, Gerhard C. ;

Holmberg, Leona ;

Krem, Maxwell M. ;

Lee, Cindy ;

Lekakis, Lazaros ;

Lazarus, Hillard M. ;

Mian, Hira ;

Murthy, Hemant S. ;

Nathan, Sunita ;

Nishihori, Taiga ;

Parrondo, Ricardo ;

Patel, Sagar S. ;

Solh, Melhem ;

Strouse, Christopher ;

Vesole, David H. ;

Kumar, Shaji ;

Qazilbash, Muzaffar H. ;

Shah, Nina ;

D'Souza, Anita ;

Sidana, Surbhi .

CANCER, 2023, 129 (14) :2179-2191

[10] Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity [J].

Heitner, Stephen B. ;

Minnier, Jessica ;

Naher, Aynun ;

Van Woerkom, Ryan C. ;

Ritts, Alexandra ;

Ferencik, Maros ;

Broberg, Craig ;

Medvedova, Eva ;

Silbermann, Rebecca ;

Scott, Emma C. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (12) :796-802

← 1 2 3 4 5 →